佩米替尼
Tier C — Watch / tradePemigatinib · all drugs expiring in 2032 →
Targets：FGFR1、FGFR2、FGFR3
Brand：达伯坦、Pemazyre、伯坦
Indications (approved)：骨髓瘤、淋巴瘤、胆管癌、胆管上皮癌、胆道癌
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| PEMIGA-001 | 271-63-6 | 1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-002 | 504440-63-5 | 1H-pyrrolo[2,3-b]pyridine 7-oxide |
| PEMIGA-003 | 55052-28-3 | 4-chloro-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-004 | 651744-48-8 | 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-005 | 958230-19-8 | 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-006 | 1032815-07-8 | 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-007 | 1032815-08-9 | 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-008 | 4394-85-8 | morpholine-4-carbaldehyde |
| PEMIGA-009 | 2382664-55-1 | 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carbaldehyde |
| PEMIGA-010 | 2382664-58-4 | 4-((4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)morpholine |
| PEMIGA-011 | 2382664-60-8 | 4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-012 | 651734-54-2 | 2,6-difluoro-3,5-dimethoxyaniline |
| PEMIGA-013 | 2382664-61-9 | N-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-2,6-difluoro-3,5-dimethoxyaniline |
| PEMIGA-014 | 109-90-0 | isocyanatoethane |
| PEMIGA-015 | 2382664-64-2 | 1-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-1-(2,6-difluoro-3,5-dimethoxyphenyl)-3-ethylurea |
| PEMIGA-016 | 1513860-02-0 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one |
| PEMIGA-017 | 602-94-8 | 2,3,4,5,6-pentafluorobenzoic acid |
| PEMIGA-018 | 36629-42-2 | methyl 2,3,4,5,6-pentafluorobenzoate |
| PEMIGA-019 | 122590-82-3 | methyl 4-(benzylamino)-2,3,5,6-tetrafluorobenzoate |
| PEMIGA-020 | 651734-52-0 | 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid |
| PEMIGA-021 | 651734-53-1 | N-benzyl-2,6-difluoro-3,5-dimethoxyaniline |
| Pemigatinib | 1513857-77-6 | - |
| Code | CAS No. | Intermediate |
|---|---|---|
| PEMIGA-003 | 55052-28-3 | 4-chloro-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-004 | 651744-48-8 | 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-005 | 958230-19-8 | 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-022 | 915403-16-6 | 4-(ethylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-012 | 651734-54-2 | 2,6-difluoro-3,5-dimethoxyaniline |
| PEMIGA-023 | 1513859-26-1 | 5-(((2,6-difluoro-3,5-dimethoxyphenyl)amino)methyl)-N-ethyl-1H-pyrrolo[2,3-b]pyridin-4-amine |
| PEMIGA-024 | 1513857-72-1 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one |
| PEMIGA-025 | 1513860-01-9 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one |
| PEMIGA-026 | 1593816-94-4 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde |
| PEMIGA-027 | 110-91-8Available | morpholine |
| PEMIGA-016 | 1513860-02-0 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one |
| Pemigatinib | 1513857-77-6 | - |
Frequently asked questions
What are the approved indications of Pemigatinib?
Approved indications include: 骨髓瘤, 淋巴瘤, 胆管癌, 胆管上皮癌, 胆道癌.
When does the Pemigatinib patent expire?
Based on public sources, the Pemigatinib patent expires in 2032.
How many synthesis routes are recorded for Pemigatinib?
2 synthesis routes are recorded; the shortest is 7 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Pemigatinib intermediates?
1 intermediate CAS of Pemigatinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Pemigatinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24